Topotecan
Checked 2026-09-09
Relapsed SCLC; platinum-resistant ovarian or cervical cancer
One cycle
every 21 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Topotecan Cytotoxic (topoisomerase-I inhibitor) | 1.5 mg/m² IV (or 2.3 mg/m² oral) | IV | D1-5 |
Cycles
until progression
21-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Consider (10-20% FN risk)
Used in
Products
Source
NCCN Small Cell Lung Cancer; von Pawel, JCO 1999
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Cisplatin + etoposide (EP)
Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma
every 21 days × 4
Carboplatin + etoposide + atezolizumab (or durvalumab)
Extensive-stage SCLC, first line
every 21 days × 4
Tarlatamab
Extensive-stage SCLC after platinum-based chemotherapy
every 14 days
BEP
Metastatic germ cell tumour: 3 cycles good risk, 4 cycles intermediate or poor risk
every 21 days × 3
Carboplatin + paclitaxel
Ovarian cancer adjuvant or neoadjuvant (6 cycles); advanced endometrial cancer with pembrolizumab or dostarlimab; NSCLC
every 21 days × 6
Carboplatin + paclitaxel + bevacizumab, then bevacizumab maintenance
Stage III-IV ovarian cancer, especially with residual disease or ascites
every 21 days × 6
Weekly paclitaxel
Platinum-resistant ovarian cancer (with or without bevacizumab); metastatic breast cancer
every 28 days
Pegylated liposomal doxorubicin
Platinum-resistant or partially platinum-sensitive ovarian cancer; Kaposi sarcoma
every 28 days